Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New inhaled drug offers hope for patients with stubborn lung infection

NCT ID NCT06585020

First seen Nov 19, 2025 · Last updated Apr 30, 2026 · Updated 22 times

Summary

This study tests whether adding an inhaled antibiotic (amikacin liposome suspension) to standard treatment helps clear a rare lung infection caused by Mycobacterium xenopi. The infection is difficult to treat and requires long-term medication. About 190 adults with this infection will receive either standard care alone or standard care plus the inhaled drug. The main goal is to see if the added drug speeds up sputum conversion (when the bacteria are no longer found in mucus).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Amiens-Picardie

    RECRUITING

    Amiens, 80054, France

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.